Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Clinical trial NCT03385486 · UNKNOWN
Trial details
- NCT number
- NCT03385486
- Sponsor
- Taiga Biotechnologies, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-02
- Primary completion
- 2023-02-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.